MBOT
Microbot Medical Inc
1.40$
+2.2%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 81.7% | 71.7% | 98.4% | 99.2% | 95.7% | 96.8% | 96.1% | 94.7% | 92.4% | 95.1% | 96.5% | 97.9% | |
| 77.1% | 57.1% | 80.4% | 97.9% | 86.0% | 77.5% | 74.8% | 80.5% | 26.4% | 29.6% | 51.6% | 4.8% | |
| 77.1% | 57.1% | 80.4% | 97.9% | 86.0% | 84.3% | 93.8% | 92.4% | 86.8% | 76.7% | 90.7% | 96.4% | |
| 1.3% | 0.3% | 0.4% | 0.3% | 1.1% | 0.3% | 1.3% | 1.0% | 1.1% | 17.9% | 5.0% | 0.3% | |
| -1.3% | 11.2% | 0.0% | 0.7% | – | -7.1% | 0.0% | -1.0% | -1.1% | -0.5% | 0.0% | 0.7% | |
| 0.2% | 24.6% | 1.6% | 0.8% | 4.3% | 0.6% | 3.9% | 5.3% | 7.6% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 1.1% | 0.2% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 81.9% | 101.6% | 49.6% | 9.6% | 78.2% | 15.0% | 7.5% | 14.2% | 23.6% | 45.9% | 41.5% | 4.9% | |
| 35.5% | 46.3% | 23.2% | 4.8% | 78.2% | 13.0% | 5.1% | 11.8% | 21.7% | 45.5% | 40.8% | 4.2% | |
| 14.5% | 6.7% | 2.3% | – | – | 0.4% | 0.7% | 1.7% | 3.0% | 2.3% | 1.2% | 0.4% | |
| 1.0% | 2.2% | 6.0% | 0.7% | 10.3% | 0.8% | 1.0% | 1.7% | 1.2% | 4.3% | 2.7% | 0.6% | |
| 31.9% | 42.0% | 2.3% | 0.0% | – | – | – | – | – | – | – | – | |
| 18.1% | -1.6% | 50.4% | 90.4% | 21.8% | 85.0% | 92.5% | 85.8% | 76.4% | 54.1% | 58.5% | 95.1% | |
| -1,296.1% | -2,152.3% | -387.0% | -187.2% | -457.5% | -94.6% | -168.5% | -331.6% | -721.0% | -954.7% | -1,507.9% | -127.6% | |
| 0.1% | 0.3% | 28.3% | 80.9% | 146.4% | 11.5% | 27.1% | 42.4% | 76.1% | 122.5% | 259.4% | 56.2% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.